EltaMD Appears in 32.3% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.

Answer Capsule

In November 2026, EltaMD appeared in 250 of 773 AI answers included in the Dermatologist Recommended Skin Care Brands benchmark (32.34%). It received 153 recommendations (19.79%), with 38 Top 3 placements and 21 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.

Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. The historical results show how the figures changed across available months. Different monthly samples limit those comparisons, and conflicting AI claims require verification before corrections are proposed.

Current AI visibility

Questions This Section Answers

• How do EltaMD mentions, recommendations and placements compare with its Dermatologist Recommended Skin Care Brands peers?

EltaMD recorded 250 mentions (32.34%) and 153 recommendations (19.79%) across 773 answers included in the benchmark. Top 3 placements numbered 38; first-place recommendations numbered 21. Framing among its mentions was 161 positive, 89 neutral and 0 negative.

EltaMD appears in roughly a third of the benchmark answers and is recommended in about a fifth, placing it seventh overall. The gap between mentions and recommendations is the useful signal: the brand is discussed far more often than it is affirmatively endorsed. That gap, not raw reach, is where the agency's work should start.

Placement is thinner still. EltaMD rarely lands in the top three or at first place, so even when it is recommended it is usually one option among several. Framing is not the problem, since almost no negative wording was recorded. The opportunity is to earn more affirmative endorsements within the answers where the brand already appears. We would build a visibility scorecard that tracks mentions, recommendations and placements separately, so the client can see which measure moves.

We would also flag that the benchmark answers still need verification before any claim about EltaMD is treated as fact.

What changed since last month

Questions This Section Answers

• How did EltaMD counts and coverage differ across the available monthly snapshots?

From October 2026 to November 2026, EltaMD's mention count fell from 251 to 250, while its recommendation count fell from 245 to 153. The recommendation rate was 31.82% and 19.79% respectively.

The monthly record shows a clear break in November. Mentions held almost flat, but recommendations dropped sharply and top-three placements fell by more than half. First-place counts moved only slightly, so the change is concentrated in the middle of the recommendation range rather than at the very top.

Because each month is a separate sample of answers, the November figures are not directly comparable with October's. The observed movement is real within the recorded data, but the record does not explain why it happened, and we would not present it as a trend until another month confirms it.

For the client, the practical point is that recommendation strength is more fragile than mention volume. We would treat the November result as a prompt to examine which answer contexts stopped endorsing EltaMD, not as evidence of a lasting decline.

Step 1. Measure

Questions This Section Answers

• What should the agency measure and verify first for EltaMD?

AI answers contained 0 conflicting claims about EltaMD: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.

No conflicting claims about EltaMD were recorded in the captured answers, so there is no fact-check queue to work through at this stage. That is a clean starting position, but it is not proof that every statement about the brand is accurate; it means nothing in this sample contradicted itself or the record.

We would still build a scoped fact-review register, because the absence of conflicts now does not guarantee the same next month. The register would list the claims that matter most to the brand, assign an owner to each and set the evidence required before any statement is treated as settled.

A visibility comparison would sit alongside it, showing where EltaMD is mentioned versus recommended. Together these give the client a priority order: protect the claims first, then work on endorsement.

Step 2. Make the website consistent

Questions This Section Answers

• Which recorded claim differences about EltaMD should be verified before proposed page edits?

No results are available for this part of the analysis.

Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.

This part of the analysis returned no results, so there are no disputed topics to resolve and no page-level conflicts to reconcile. We would not invent a consistency problem where the evidence shows none.

What we can propose is a verification step before any page work begins. If a claim about EltaMD later appears in an answer, the first task is to confirm the entity, the date and the source, since different dates can make two statements look contradictory when they are not.

Only after that check would we draft a page brief. The brief would use approved facts and would not decide which version of a disputed claim is true; that decision belongs to the client's own evidence.

Step 3. Align the external narrative

Questions This Section Answers

• Which cited third-party pages are relevant to fact review for EltaMD?

These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.

The cited pages selected for review are mostly retailer and dermatology-clinic product listings, each appearing once in the captured answers. None of them is linked to a conflicting claim, so there is no correction request to justify at this point.

That does not mean the pages are accurate. Their current contents still need checking against primary sources before the agency approaches anyone. A citation also does not show that a page influenced an answer, so we would not treat these listings as levers until we understand how they are used.

Our proposed work is a source review: confirm what each page currently says, identify any statement that conflicts with verified brand facts, and only then prepare a polite, evidence-backed request. Publishers control their own pages, and many requests will reasonably be declined.

Step 4. Optimize priority company pages

Questions This Section Answers

• Which observed EltaMD website pages should receive review briefs?

The company's website was cited 9 times across 9 distinct page addresses; the table shows 8 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.

EltaMD's own site was cited across a small set of product pages, and most of those citations appeared in answers that also recommended the brand. That makes the owned pages a sensible place to concentrate brief-writing effort, since they already appear in the answer set.

The page list covers sunscreen, moisturizer and cleanser products, including the UV Clear and UV Physical lines. We would write briefs for the pages that already attract citations first, using approved product facts and the questions buyers actually ask, rather than rewriting the whole catalogue.

Each brief would state what the page should answer, which facts are approved and who signs off. A cited page is not automatically a page that drove a recommendation, so we would measure any change separately from the brief work itself.

Step 5. Publish around buyer questions

Questions This Section Answers

• Which observed buyer questions support content briefs for EltaMD?

These are recorded answer observations, not search volume, verified demand, or proof of missing website content.

The recorded questions are broad brand-comparison prompts: which line dermatologists recommend, which brands are best, and top-ten style lists. EltaMD appears in most of these answers and is recommended in several, which suggests the brand already has a foothold in comparison content.

These are answer observations, not search volume, so we would not treat them as proven demand. Before proposing new pages, we would check whether the site already covers these questions and whether existing pages answer them well.

Where coverage is thin, we would draft buyer-question briefs that address the comparison directly, using approved facts and clear product distinctions. The aim is to give the brand a stronger, more specific presence in answers where it currently appears only in passing.

Our 90-day action plan

Questions This Section Answers

• How should the agency sequence the proposed EltaMD work and judge completion?

The first month is about establishing a reliable baseline: a visibility scorecard, a scoped fact-review register and a shortlist of pages and sources worth examining. Each record gets an owner, an evidence requirement and a review status, so nothing sits unresolved.

The second month turns that groundwork into approved page briefs and, where justified, publisher requests. Confirmed edits, no-change decisions, requests and responses are logged separately, so the client can see what was actually done rather than what was hoped for.

The third month adds buyer-content briefs and a fresh scorecard. We would report completed work separately from measured answer outcomes, and we would not claim that any deliverable caused a change in visibility.

Methodology

Questions This Section Answers

• How are EltaMD answer metrics and citation populations defined?

This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 773 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.

An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.

The wider citation analysis covers 800 captured answers and 5811 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.

Monthly sample coverage:

The answer samples differ between months. These comparisons show how the recorded results changed; they do not establish why they changed.

The report covers a single month, and the exact dates when the answers were collected have not been verified. Visibility rates rest on answers that met the benchmark's inclusion rules, and a company counts as recommended only when an answer both endorses it and uses positive wording.

Answers can mention several companies, so company counts cannot be added to reach a total number of answers. Sentiment describes answer wording, not customer satisfaction. The citation analysis covers a wider set of captured answers than the benchmark, and cited pages still need independent checking.

Monthly samples differ, so comparisons show how recorded results changed, not why.

Our first three priorities

First, protect the factual base. Even with no conflicts recorded, we would build the fact-review register now, because a clean month is the cheapest time to agree which claims are approved and who owns them.

Second, concentrate page briefs on the owned product pages that already appear in answers, starting with the sunscreen and moisturizer lines. These are the pages where a clearer, better-sourced answer could plausibly strengthen an endorsement, though we would measure any effect separately from the work.

Third, treat the November recommendation drop as a question to investigate rather than a conclusion. We would examine which answer contexts stopped endorsing EltaMD and pair that with buyer-question briefs for the comparison prompts where the brand already appears.